生物标记物在乳腺导管原位癌中的应用现状及进展  

Application status and progress of biomarkers for ductal carcinoma in situ

作　　者：张永辉[1] 曹旭晨[1] 

机构地区：[1]天津医科大学附属肿瘤医院乳腺一科乳腺癌防治教育部重点实验室,天津300060

出　　处：《临床肿瘤学杂志》2015年第5期455-459,共5页Chinese Clinical Oncology

摘　　要：乳腺导管原位癌(DCIS)是乳腺癌的前驱病变已被普遍认可,但对DCIS的生物及临床行为的认识仍显不足。DCIS和致死性的浸润性乳腺癌(IBC)不同,为低风险疾病,研究侧重点为预测其进展为浸润性癌的发生风险以及保乳术后局部复发风险。生物标记物在IBC的预后评估及指导个体化临床治疗方面均发挥了很大的作用,但其在DCIS中的应用仍值得进一步研究。本文主要就DCIS生物标记物的风险预测及其临床应用价值进行了综述。Although there is a broad consensus that ductal carcinoma in situ（ DCIS） of the breast is the precursor lesions of infiltrated breast carcinoma（ IBC） . The understanding of the biology and clinical behavior of DCIS is currently inadequate. Invasive breast cancer is a fatal disease, while DCIS is an indolent disease. In order to guide individualized clinical treatment, the focus is on the prediction of the risk of progression from DCIS to IBC and the risk of local recurrence after breast conserving surgery. Biomarkers have guided the clinical work and predicted different risk of IBC in recent years, but their application in DCIS is worthy of further in？vestigation. This review highlights the biomarkers in DCIS and its role of risk prediction.

关 键 词：乳腺导管原位癌 生物标记物 复发 预后 

分 类 号：R737.9[医药卫生—肿瘤]